# Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

> **NCT00876863** · PHASE2 · COMPLETED · sponsor: **Sangamo Therapeutics** · enrollment: 49 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** CERE-110: Adeno-Associated Virus injection Surgery
- **PROCEDURE:** Placebo Surgery

## Key facts

- **NCT ID:** NCT00876863
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2015-08-13
- **Final completion:** 2015-08-13
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00876863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00876863, "Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00876863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*